Brief: Caplin Point Laboratories Says Unit Final Approval By USFDA
20/09/2023 06:27
Sept 20 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS :
* GRANT OF FINAL APPROVAL BY USFDA FOR ANDA NOREPINEPHRINE BITARTRATE
INJECTION
USP, TO UNIT
Further company coverage: CAPL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees